Flood Gates Have Opened: 15 (!) IPOs on schedule

What a wild Monday in the IPO launch department!

A total of nine deals launched, eight of which will debut on Friday! Additionally, a high-profile consumer name, Bumble Inc., launched on Tuesday morning for a debut on Thursday (2/11). Here’s how the schedule is looking for the rest of the week.

Wednesday (2/3) Debut

• On24 Inc.(ONTF) — They provide a leading, cloud-based digital experience platform that enables businesses to convert customer engagement into revenue through interactive webinar experiences, virtual event experiences and multimedia content experiences.
• Telus International (Cda), Inc. (TIXT) — They are a leading digital customer experience innovator that designs, builds and delivers next-generation solutions for global and disruptive brands.

Thursday (2/4) Debut

• Atotech Limited (ATC) — They are the leading global provider of specialty electroplating solutions delivering chemistry, equipment, and service for high-growth technology applications.
• Evaxion Biotech A/S (EVAX) —  They are a clinical-stage AI-immunology™ platform company using their proprietary artificial intelligence, or AI, technology, engineering expertise and drug development know-how to simulate the human immune system and generate predictive models to identify and develop novel immunotherapies for the treatment of various cancers, bacterial diseases and viral infections.
• Loan Depot Inc. (LDI)  —   LoanDepot is a leading technology-enabled U.S. consumer lending platform.
• Landos Biopharma Inc. (LABP) —  They are a clinical-stage biopharmaceutical company focused on the discovery and development of oral therapeutics for patients with autoimmune diseases that are the first to target new mechanisms of action, including the LANCL2, NLRX1 and PLXDC2 immunometabolic pathways.according to the CIC report.
• Sana Biotechnology Inc. (SANA) — They have long-term aspirations to be able to control or modify any gene in the body, to replace any cell that is damaged or missing, and to markedly improve access to cellular and gene-based medicines.

Friday (2/5) Debut

• Angion Biomedica Corp. (ANGN) —   They are a late-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases.
• Bolt Therapeutics Inc (BOLT) —    They are a clinical-stage immuno-oncology company developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems.
• Immunocore Holdings plc (IMCR) —    They are a late-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease – designed to treat a broad range of diseases, including cancer, infectious and autoimmune.
• Lucira Health Inc (LHDX) —   They are a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits.
• Pharvaris B.V. (PHVS) —   They are a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for rare diseases with significant unmet need, initially focused on angioedema and other bradykinin-mediated diseases.
• Sensei Biotherapeutics, Inc (SNSE) —    They are an immunotherapy company engaged in the discovery and development of next-generation therapies with an initial focus on treatments for cancer.
• Terns Pharmaceuticals Inc. (TERN) —    They are a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases.
• Vor Biopharma Inc (VOR) —    The mission of Vor Biopharma is to develop transformative treatments for patients suffering from hematological malignancies.

Indicating for IPOs or Secondary offerings? Place IPO Boutique on your team.

https://www.ipoboutique.com/blog/register/